NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT00329043 2025-12-26
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01254864 2025-01-27
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00599313 2018-10-25
Phase II Sunitinib Prog Met AIPC
US Oncology Research
Phase 2 Completed
NCT01803503 2016-06-22
Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors
National University Hospital, Singapore
Phase 2 Unknown
NCT00734851 2015-12-23
Multimodality Phase II Study in Prostate Cancer
Duke University
Phase 2 Terminated
NCT00672594 2014-08-04
Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy
Duke University
Phase 2 Completed
NCT00748358 2013-09-18
PROSUT
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT00299741 2012-12-19
Study of SU11248 in Men With Advanced Prostate Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT00550810 2011-12-07
SMART
AHS Cancer Control Alberta
Phase 2 Unknown